Regional Variation in Cardiovascular Genes Enables a Tractable Genome Editing Strategy
Authors:
- Vikki A. KrysovVKVikki A. Krysov
- Rachel H. WilsonRWRachel H. Wilson
- Nicholas S. TenNTNicholas S. Ten
- Nathan YoultonNYNathan Youlton
- Hannah N. De JongHJHannah N. De Jong
- Shirley SuttonSSShirley Sutton
- Yong HuangYHYong Huang
- Chloe M. ReuterCRChloe M. Reuter
- Megan E. GroveMGMegan E. Grove
- Matthew T. WheelerMWMatthew T. Wheeler
- Euan A. AshleyEAEuan A. Ashley
- Victoria N. ParikhVPVictoria N. Parikh
Open Access
- 1 April 2024
- journal article
- research article
- Published by Wolters Kluwer Health in Circulation: Genomic and Precision Medicine
- Vol. 17 (2) , e004370
Abstract
BACKGROUND: To realize the potential of genome engineering therapeutics, tractable strategies must be identified that balance personalized therapy with the need for off-the-shelf availability. We hypothesized that regional clustering of pathogenic variants can inform the design of rational prime editing therapeutics to treat the majority of genetic cardiovascular diseases with a limited number of reagents. METHODS: We collated 2435 high-confidence pathogenic/likely pathogenic (P/LP) variants in 82 cardiovascular disease genes from ClinVar. We assessed the regional density of these variants by defining a regional clustering index. We then combined a highly active base editor with prime editing to demonstrate the feasibility of a P/LP hotspot-directed genome engineering therapeutic strategy in vitro. RESULTS: P/LP variants in cardiovascular disease genes display higher regional density than rare variants found in the general population. P/LP missense variants displayed higher average regional density than P/LP truncating variants. Following hypermutagenesis at a pathogenic hotspot, mean prime editing efficiency across introduced variants was 57±27%. CONCLUSIONS: Designing therapeutics that target pathogenic hotspots will not only address known missense P/LP variants but also novel P/LP variants identified in these hotspots as well. Moreover, the clustering of P/LP missense rather than truncating variants in these hotspots suggests that prime editing technology is particularly valuable for dominant negative disease. Although prime editing technology in relation to cardiac health continues to improve, this study presents an approach to targeting the most impactful regions of the genome for inherited cardiovascular disease.Keywords
All Related Versions
This publication has 21 references indexed in Scilit:
- CHOPCHOP v3: expanding the CRISPR web toolbox beyond genome editingNucleic Acids Research, 2019
- Regional Variation in RBM20 Causes a Highly Penetrant Arrhythmogenic CardiomyopathyCirculation: Heart Failure, 2019
- UniProt: a worldwide hub of protein knowledgeNucleic Acids Research, 2018
- Directed evolution using dCas9-targeted somatic hypermutation in mammalian cellsNature Methods, 2016
- Multidimensional structure-function relationships in human β-cardiac myosin from population-scale genetic variationProceedings of the National Academy of Sciences, 2016
- Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular PathologyGenetics in Medicine, 2015
- Allele-Specific Silencing of Mutant Myh6 Transcripts in Mice Suppresses Hypertrophic CardiomyopathyScience, 2013
- A novel mutation in the KCNH2 gene associated with short QT syndromeJournal of Molecular and Cellular Cardiology, 2011
- Insights into Human β-Cardiac Myosin Function from Single Molecule and Single Cell StudiesJournal of Cardiovascular Translational Research, 2009
- GermlineBRAFmutations in Noonan, LEOPARD, and cardiofaciocutaneous syndromes: Molecular diversity and associated phenotypic spectrumHuman Mutation, 2009